FMP
CNS Pharmaceuticals, Inc.
CNSP
NASDAQ
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
0.106 USD
0.0037 (3.5%)
2023
2022
2021
2020
0
0
0
0
4.13k
11.76k
13.07k
11.1k
-4.13k
-11.76k
-13.07k
-11.1k
18.87M
15.27M
14.03M
9.45M
14.1M
9.3M
9.35M
5.06M
4.77M
5.97M
4.68M
4.39M
0
0
0
0
4.77M
5.97M
4.68M
4.39M
0
0
0
0
-18.87M
-15.27M
-14.03M
-9.45M
13.88k
-7.03k
-9.29k
-3.26k
-18.85M
-15.27M
-14.04M
-9.46M
0
7.03k
9.29k
3.26k
-18.85M
-15.27M
-14.5M
-9.46M
-251.35
-560.83
-852.66
-859.81
-250.19
-560.83
-825.04
-853.68
75k
27.23M
17M
11M
75.35k
27.23M
17.57M
11.08M
-18.86M
-15.26M
-14.47M
-9.44M
2023
2022
2021
2020
-50.72M
-34.98M
-20.95M
-11.49M
-18.85M
-15.27M
-14.5M
-9.46M
0
0
0
0
0
0
0
0
-69.57M
-50.72M
-34.98M
-20.95M
-18.85M
-15.73M
-14.04M
-9.46M
2023
2022
2021
2020
4.93k
5.66k
16.11k
23.43k
4.13k
11.76k
13.07k
11.1k
-3.9k
-4.42k
-5.75k
-17.95k
4.7k
-1.67k
8.79k
30.28k
2023
2022
2021
2020
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.